TWINAQT is a two-drug fixed-dose antiretroviral combination developed for simplified HIV-1 therapy in virologically suppressed adults.
Mechanism of action:
Dolutegravir inhibits HIV integrase, preventing viral DNA from integrating into host cells
Lamivudine inhibits reverse transcriptase, impairing viral replication
Recommended for:
Adults with sustained virologic suppression
Maintenance therapy as a switch from triple ART
Patients with no history of resistance to either drug
HIV-1 maintenance therapy in adults with viral load <50 copies/mL
As a dual therapy alternative to three-drug regimens
Take one tablet daily by mouth, with or without food. Adherence is crucial to maintain viral suppression. This medication should be prescribed and monitored by a healthcare professional.
Known hypersensitivity to any component
Resistance to dolutegravir or lamivudine
Co-administration with doxorubicin, rifampicin, or St. John’s wort
Sleep disturbances
Headache
Nausea
Fatigue
Elevated liver enzymes
Hypersensitivity reactions
